A lawsuit was filed on behalf of investors in Antares Pharma Inc (NASDAQ:ATRS) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 11/15/2017 -- The Shareholders Foundation announces that an investor in NASDAQ:ATRS shares filed a lawsuit against Antares Pharma Inc over alleged Securities Laws violations.
Investors who purchased shares of Antares Pharma Inc (NASDAQ:ATRS) have certain options and for certain investors are short and strict deadlines running. Deadline: December 22, 2017. NASDAQ:ATRS investors should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
Antares Pharma, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. Antares Pharma Inc's product Xyosted (originally known as QuickShot Testosterone or QST) has been among the Company's lead product candidates at all relevant times. Antares Pharma Inc announced its submission of a New Drug Application ("NDA") for Xyosted to the U.S. Food and Drug Administration ("FDA") on December 21, 2016.
On October 12, 2017, Antares Pharma Inc announced that, on October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration ("FDA") stating that, as part of their ongoing review of the Company's NDA for XYOSTED™ injection, they have identified deficiencies that preclude the continuation of the discussion of labeling and postmarketing requirements/commitments at this time.
On October 20, 2017, Antares Pharma Inc announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for Xyosted, "indicat[ing] that the FDA cannot approve the NDA in its present form." Antares Pharma Inc stated, in part that "the FDA is concerned that XYOSTED could cause a clinically meaningful increase in blood pressure" and also "raised a concern regarding the occurrence of depression and suicidality."
The plaintiff claims that between December 21, 2016, and October 12, 2017, the made false and/or misleading statements and/or failed to disclose that Antares had provided insufficient data to the FDA in connection with its NDA for Xyosted, that accordingly, Antares had overstated the approval prospects for Xyosted, and that as a result of the foregoing, Antares' public statements were materially false and misleading at all relevant times.
Those who purchased shares of Antares Pharma Inc (NASDAQ:ATRS) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego